Characteristics, treatment patterns, and survival from three cohorts of advanced or metastatic cancer patients using healthcare claims data in the United States.

被引：0
|
作者：
Lamy, Francois-Xavier
Beachler, Daniel C.
Russo, Leo J.
Lanes, Stephan
Dinh, Jade
Taylor, Devon H.
Yin, Ruihua
Jamal-Allial, Aziza
Verpillat, Patrice
机构：
[1] Merck KGaA, Global Epidemiol, Darmstadt, Germany
[2] HealthCore Inc, Safety & Epidemiol, Wilmington, DE USA
[3] Pfizer Inc, Collegeville, PA USA
[4] HealthCore Inc, Safety & Epidemiol, Andover, MA USA
[5] HealthCore Inc, Safety & Epidemiol, Alexandria, VA USA
[6] HealthCore Inc, Safety & Epidemiol, Watertown, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e13082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13082
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Factors associated with decreased survival in epithelial ovarian cancer patients from the southern United States.
    Stewart, Sherri L.
    Thompson, Trevor D.
    Moore, Angela R.
    Rim, Sun Hee
    Wike, Jennifer M.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (07) : 50 - 51
  • [32] Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in US Healthcare Claims Data
    Choong, Casey K.
    Ford, Janet H.
    Nyhuis, Allen W.
    Joshi, Shivang G.
    Robinson, Rebecca L.
    Aurora, Sheena K.
    Martinez, James M.
    HEADACHE, 2017, 57 (09): : 1359 - 1374
  • [33] Treatment patterns following first-line pertuzumab plus trastuzumab in patients with HER2+metastatic breast cancer in the United States.
    Mehta, Sandhya
    Pavilack, Melissa
    Xie, Jipan
    Ionescu-Ittu, Raluca
    Nie, Xiaoyu
    Lei, Yin
    Kwong, Jackie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data
    Hill, Nathan
    Rosenblatt, Lisa
    Yin, Xin
    Haley, Valerie
    Nguyen, Chi
    Barron, John
    Vilanova, David
    George, Saby
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 398 - 398
  • [35] Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United States
    Davis, Jessica A.
    Cui, Zhanglin Lin
    Ghias, Madiha
    Li, Xiaohong
    Goodloe, Robert
    Wang, Chunxiao
    Liepa, Astra M.
    Hess, Lisa M.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (03) : 949 - 957
  • [36] Development and validation of coding algorithms to identify patients with incident lung cancer in United States healthcare claims data
    Beyrer, Julie
    Nelson, David R.
    Sheffield, Kristin M.
    Huang, Yu-Jing
    Ellington, Tim
    Hincapie, Ana L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (11) : 1465 - 1479
  • [37] Using Data from a Sickness Fund Claims Database to Assess the Treatment Patterns and Healthcare Resource Utilization among Patients with Metastatic Renal Cell Carcinoma in Germany
    Boegemann, Martin
    Zagorska, Aleksandra
    Akumo, Divine
    El Hadad, Laila
    Pignot, Marc
    UROLOGIA INTERNATIONALIS, 2020, 104 (11-12) : 982 - 993
  • [38] Using diagnosis codes in claims data to identify cohorts of breast cancer patients following initial treatment
    Franc, Benjamin L.
    Thombley, Robert
    Luo, Yanting
    John Boscardin, W.
    Rugo, Hope S.
    Seidenwurm, David
    Adams Dudley, R.
    BREAST JOURNAL, 2020, 26 (07): : 1472 - 1474
  • [39] Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data Base
    Sineshaw, Helmneh M.
    Jemal, Ahmedin
    Thomas, Charles R., Jr.
    Mitin, Timur
    CANCER, 2016, 122 (13) : 1996 - 2003
  • [40] Real-world data on overall survival associated with biweekly versus weekly cetuximab among metastatic colorectal cancer (mCRC) patients in the United States.
    Agg, Himani
    Han, Yimei
    Cui, Zhanglin Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345